{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:57Z","timestamp":1789770297557,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>For women infected with the human immunodeficiency virus (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>) who become pregnant, the use of combination antiretroviral therapy (<jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>) significantly reduces transmission of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> from mother to child. Selection of an appropriate <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> regimen for use among pregnant women requires consideration of numerous factors including maternal and fetal safety, antiretroviral pharmacokinetics, and regimen efficacy. Optimization of antiretroviral pharmacokinetics during pregnancy requires special consideration because pregnancy\u2010associated changes in drug absorption, distribution, metabolism, and excretion are known to occur throughout pregnancy and postpartum. Understanding antiretroviral placental transfer may offer additional insight into each drug's potential role in preventing <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> transmission in utero and may also have implications regarding viral resistance in cases where transmission does occur. In this review, we summarize key published data describing antiretroviral pharmacokinetics in pregnant women, providing suggestions for clinical application of these data where appropriate.<\/jats:p>","DOI":"10.1002\/phar.1626","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T22:41:21Z","timestamp":1440196881000},"page":"838-855","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antiretroviral Pharmacokinetics in Pregnant Women"],"prefix":"10.1002","volume":"35","author":[{"given":"Elise M.","family":"Gilbert","sequence":"first","affiliation":[{"name":"Department of Pharmacy Northwestern Memorial Hospital Chicago Illinois"},{"name":"Department of Pharmacy Practice Chicago State University College of Pharmacy Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Darin","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine Division of Infectious Diseases and Center for Global Health Northwestern University Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice College of Pharmacy University of Nebraska Medical Center Omaha Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena M.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Northwestern Memorial Hospital Chicago Illinois"},{"name":"Department of Pharmacy Practice Chicago College of Pharmacy Midwestern University Downers Grove Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,21]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Panel on Treatment of HIV\u2010Infected Pregnant Women and Prevention of Perinatal Transmission.Recommendations for Use of Antiretroviral Drugs in Pregnant HIV\u20101\u2010Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available fromhttp:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf. Accessed August 3 2014."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/beog.2001.0231"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733050-00002"},{"key":"e_1_2_8_5_1","unstructured":"United States National Library of Medicine.DailyMed. Available fromhttp:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm. Accessed October 29 2014."},{"key":"e_1_2_8_6_1","unstructured":"Liverpool HIV Pharmacology Group.Fact Sheets.www.hiv-druginteractions.org. University of Liverpool. Available fromhttp:\/\/www.hiv-druginteractions.org\/FactSheets.aspx. Accessed August 6 2014."},{"key":"e_1_2_8_7_1","unstructured":"Antiretroviral Pregnancy Registry Steering Committee.Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 July 2014. Available fromhttp:\/\/www.apregistry.com\/forms\/interim_report.pdf. Accessed January 21 2015."},{"key":"e_1_2_8_8_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010Infected adults and adolescents. Available fromhttp:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed August 18 2014."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000210609.52836.d1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03469-14"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12457"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835c208b"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1293.2011.00965.x","article-title":"Effect of pregnancy on emtricitabine pharmacokinetics","volume":"4","author":"Stek AM","year":"2012","journal-title":"HIV Med"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00370-11"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01523-08"},{"key":"e_1_2_8_16_1","unstructured":"PowellMB BestBM MirochnickM et\u00a0al.Changes in tenofovir population pharmacokinetics during pregnancy. Poster abstract PP_03. 14th International Workshop on Clinical Pharmacology of HIV Therapy;2013; Amsterdam The Netherlands."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.2.226"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/315152"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000231"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823ff052"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000279"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829c48ad"},{"key":"e_1_2_8_23_1","unstructured":"RamgopalM OsiyemiO ZorillaC et\u00a0al.Pharmacokinetics of Etravirine (ETV) in HIV\u20101\u2010infected Pregnant Women. Abstract 893. The Conference on Retroviruses and Opportunistic Infections;2015; Seattle WA."},{"key":"e_1_2_8_24_1","unstructured":"BestB ColbersA WangJ et\u00a0al.Etravirine Pharmacokinetics During Pregnancy and Postpartum. Abstract 892. The Conference on Retroviruses and Opportunistic Infections;2015; Seattle WA."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt095"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181e9871b"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00551.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00631-10"},{"key":"e_1_2_8_29_1","unstructured":"MirochnickM TranA BestB et\u00a0al.Pharmacokinetics of Rilpivirine in HIV\u2010Infected Women During Pregnancy and Postpartum. Abstract 894. The Conference on Retroviruses and Opportunistic Infections;2015; Seattle WA."},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3851\/IMP2473","article-title":"Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review","volume":"3","author":"Eley T","year":"2013","journal-title":"Antivir Ther"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31820fd093"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2820"},{"key":"e_1_2_8_33_1","unstructured":"L\u00eaMP CharpentierC SoulieC et\u00a0al.Safety Efficacy and PK of Atazanavir\/Ritonavir (300\/100\u00a0mg QD) in HIV+ Pregnant Women Cohort. Abstract 889. The Conference on Retroviruses and Opportunistic Infections;2014; Boston MA."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318289b4d2"},{"key":"e_1_2_8_35_1","unstructured":"CapparelliEV BestBM StekA et\u00a0al.Pharmacokinetics of Darunavir Once or Twice Daily During and After Pregnancy. Poster abstract P_72. 3rd International Workshop on HIV Pediatrics;2011; Rome Italy."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12047"},{"key":"e_1_2_8_37_1","unstructured":"ColbersA Molt\u00f3J IvanovicJ et\u00a0al.Low Darunavir Exposure During Pregnancy With 800\/100\u00a0mg Darunavir\/r QD Dosing. Abstract 887. The Conference on Retroviruses and Opportunistic Infections;2014; Boston MA."},{"key":"e_1_2_8_38_1","unstructured":"CrauwelsH BaughB RyanB et\u00a0al.Total and unbound pharmacokinetics of once\u2010daily darunavir\/ritonavir in HIV\u20101 infected pregnant women. Abstract O_15. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy;2014; Washington DC."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318285d918"},{"key":"e_1_2_8_40_1","unstructured":"CapparelliEV StekA BestB et\u00a0al.Boosted fosamprenavir pharmacokinetics during pregnancy. Abstract 908\/Poster T\u2010110. The Conference on Retroviruses and Opportunistic Infections;2010; San Francisco CA."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d6c9ed"},{"key":"e_1_2_8_42_1","unstructured":"DarinK PodanyAT AndersonPL et\u00a0al.Marked increase in lopinavir clearance occurs between early and late second trimester of pregnancy: a population analysis of a diverse clinical cohort. Abstract P_45. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy;2014; Washington DC."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02599-13"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP2328","article-title":"Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women","volume":"2","author":"Fayet\u2010Mello A","year":"2013","journal-title":"Antivir Ther"},{"key":"e_1_2_8_45_1","unstructured":"BestBM CapparelliEV StekA et\u00a0al.Raltegravir Pharmacokinetics during Pregnancy. Abstract H\u20101668a. Interscience Conference on Antimicrobial Agents and Chemotherapy;2010; Boston MA."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ366"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1250-5"},{"key":"e_1_2_8_48_1","unstructured":"JeantilsV MessaoudenH CarbillonL.Pregnancy and a Regimen Containing Raltegravir: a Pilot Study on the Materno Foetal Safety. Abstract H\u20101463. ICAAC;2013; Denver CO."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835a9aeb"},{"key":"e_1_2_8_50_1","unstructured":"ColbersA BestB WangJ et\u00a0al.A Comparison of the Pharmacokinetics of Maraviroc During Pregnancy and Postpartum. Abstract 931. The Conference on Retroviruses and Opportunistic Infections;2013; Atlanta GA."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01821-12"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1626","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:35:10Z","timestamp":1761057310000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,21]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/phar.1626"],"URL":"https:\/\/doi.org\/10.1002\/phar.1626","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,21]]},"assertion":[{"value":"2015-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}